Fractyl Health (GUTS) Stock Price

Fractyl Health Price

NYSE·CLOSED
4.03
​
Market closed

Fractyl Health's net margin stands at -73,864.5%, down from -64,242.5% several years earlier. Analysts set a median price target of 6.32 USD, implying 57.1% above the current price. Of 11 analysts, 9 rate the stock a buy — an overall Buy consensus.

Fractyl Health stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fractyl Health business model & stock analysis

Fractyl Health Inc is a US-based company operating in industry. The company is headquartered in Lexington, Massachusetts and currently employs 88 full-time employees. The company went IPO on 2024-02-02. Fractyl Health, Inc. is a metabolic therapeutics company. The firm is focused on approaches to the treatment of metabolic diseases, including type 2 diabetes (T2D) and obesity. The Revita DMR System (Revita), the Company’s lead product candidate, is an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The Revita system is designed to enable durable and repeatable metabolic improvement via hydrothermal ablation of the dysfunctional duodenal mucosa to address duodenal pathology and consequent metabolic disease progression directly. The firm is involved in enrolling is pivotal Revitalize-1 study in patients with inadequately controlled T2D. The company is also developing Rejuva, a locally administered, adeno-associated virus (AAV), delivered pancreatic gene therapy (PGTx), platform. Rejuva is designed to enable long-term remission of T2D and obesity.

Frequently asked questions about Fractyl Health

Analysts currently set an average price target of 5.34 USD for the Fractyl Health stock (median: 6.32 USD), implying +32.8 % versus the latest price. The consensus is based on 11 analyst ratings.

13 analysts currently rate the Fractyl Health stock: 11 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Fractyl Health to generate revenue of 12.43 M USD and earnings per share of -4.11 USD.

Converted at the current exchange rate, the Fractyl Health share trades at 3.60 EUR (4.03 USD).

The expected revenue of Fractyl Health is 12.43 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Fractyl Health is -630.35 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Fractyl Health is currently -0.98. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Fractyl Health stock.

The price-to-sales ratio (P/S) of Fractyl Health is currently 49.65. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Fractyl Health stock.

The Eulerpool Quality Score for Fractyl Health is 2/10.

The ISIN of Fractyl Health is US35168W1036. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Fractyl Health is GUTS. The ticker symbol is used to trade Fractyl Health shares on the stock exchange.

Fair ValueTerminal
3.86 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
—
Industry
Other
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website fractyl.com
Currency
USD
Initial public offering
Feb 2, 2024
ISIN
US35168W1036
Cusip
35168W103
Market capitalization
617.31 M USDSmall Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-0.98
P/Ee 2027
-0.85
P/Ee 2028
-1.26
P/Ee 2029
2.88
P/Ee 2030
6.29
P/Se
49.65
EV/EBIT
—
P/B Ratio
65.27
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-198.24 %
Last updated Oct 15, 2026, 6:02 AM

Fractyl Health Peer Group